Lund, Sweden, 15.00 CET, 14 April 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that new preclinical data1 has been published that further support BONESUPPORT’s ambition to develop a combination product of the company’s platform technology CERAMENT® and bisphosphonate, a pharmaceutical that counteracts osteoporosis.
In a pre-clinical long-term study D.B. Raina et al. investigated different bone active pharmaceutical combinations in order to enhance long-term bone formation in the femoral neck of osteoporotic rats. Bone formation was measured six months after local treatment and showed that CERAMENT as a carrier of bisphosphonate indicated significantly higher bone volumes than the other treatment groups.
The evidence from this long-term study validates and confirms that local delivery of a bisphosphonate in combination with CERAMENT can regenerate cancellous bone in the femoral neck canal and has clear implications for enhancing implant integration and fixation in fragile bone. Osteoporosis often leads to fragility fractures of the hip resulting in impaired quality of life and increased mortality. Augmenting the proximal femur could be an attractive treatment option to decrease the risk of fracture fixation failure and reoperation.
“The long-term preclinical results of D.B. Raina et al. confirm our previous decision to focus our research efforts on developing a combination product of CERAMENT and bisphosphonate, that could potentially reduce the risk of fracture related complications and thereby improve and prolong the lives of patients suffering from hip fractures,” said Emil Billbäck, CEO of BONESUPPORT.
1 Long Term Response to a Bioactive Biphasic Biomaterial in the Femoral Neck of Osteoporotic Rats was published in Tissue Eng Part A. 2020 Apr 3.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
+46 (0) 708 76 87 87
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits that its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2021. The company is based in Lund, Sweden, and the net sales amounted to SEK 155 million in 2019. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.